Why the study?
Does fixed-dose combination therapy targeting the renin-angiotensin system improve blood pressure control and compliance in patients with hypertension?
Does fixed-dose combination therapy targeting the renin-angiotensin system improve blood pressure control and compliance in patients with hypertension?
Fixed-dose combination therapies for hypertension improve patient compliance and blood pressure control while offering better tolerability than high-dose monotherapies.
May support RAS fixed-dose combinations to boost adherence in hypertension; leaves open randomized confirmation before practice change.
Most patients with hypertension require two or more agents from different classes to achieve BP control. Several fixed-dose combinations are available, often combining agents that target the renin angiotensin system (angiotensin-converting enzyme [ACE] inhibitors or an angiotensin receptor blockers [ARBs]) plus either thiazide diuretics or calcium channel blockers (CCBs). At low doses, these combinations may have greater efficacy and better tolerability than the respective high dose monotherapies. Combining an ARB (instead of an ACE inhibitor) with the CCB amlodipine offers efficacy with improved tolerability. This review aims to highlight the simplicity, tolerability, and convenience of fixed-dose combinations targeting the renin-angiotensin system, which can lead to improved compliance and more patients achieving BP goals.
No takes yet. Share an insight, caveat, or question.
Roland E. Schmieder (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: